TN-001
Pharmaceutical compound
From Wikipedia, the free encyclopedia
TN-001 is a non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and post-traumatic stress disorder (PTSD).[1][2][3][4][5] Its route of administration is unspecified.[1] The drug acts as a serotonin receptor modulator, including as a serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist, and has been found to produce psychoplastogenic effects without inducing the head-twitch response.[1][2][3][4][5] It is being developed by Transneural Therapeutics, a spinout of CaaMTech.[1][2][4] As of June 2025, TN-001 is in the preclinical research stage of development.[1][2][3] A clinical trial is being planned.[1] The chemical structure of the drug does not yet appear to have been disclosed.[1]
administrationUnspecified[1]
| Clinical data | |
|---|---|
| Other names | TN001 |
| Routes of administration | Unspecified[1] |
| Drug class | Serotonin receptor modulator; Non-hallucinogenic serotonin 5-HT2A receptor agonist; Psychoplastogen |
